NSRX — Nasus Pharma Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeMicro CapValue Trap

Annual income statement for Nasus Pharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2022 March 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M
Source:	PROSPECTUS	PROSPECTUS	PROSPECTUS
Standards:	USG	USG	USG
Status:	Final	Final	Final
Total Revenue	0	0	0
Selling / General / Administrative Expenses
Research And Development
Total Operating Expenses	0.004	0.002	0.002
Operating Profit	-0.004	-0.002	-0.002
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-0.004	-0.002	-0.003
Net Income After Taxes	-0.004	-0.002	-0.003
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	-0.003	-0.002	-0.003
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-0.003	-0.002	-0.003
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-0	-0	-0